内科

目的探讨二甲双胍联合二肽基肽酶-4（DPP-4）抑制剂治疗对2型糖尿病患者血糖水平、氧化应激及炎症反应的影响。方法选取2018年7月至2020年7月我院收治的2型糖尿病患者120例为研究对象，采用随机数字法分成观察组和对照组，每组60例。对照组患者给予盐酸二甲双胍治疗，观察组患者在对照组治疗的基础上给予沙格列汀治疗，持续治疗6个月。比较两组患者治疗前后的血糖、氧化应激指标及炎性因子水平。结果治疗前，两组患者的空腹血糖（FPG）、餐后2h血糖（2hPG）水平比较差异无统计学意义（P＞0.05）；治疗6个月后，两组患者的FPG、2hPG水平均显著降低，观察组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的丙二醛（MDA）、脂质过氧化氢（LHP）、谷胱甘肽过氧化物酶（GSH-Px）水平比较差异无统计学意义（P＞0.05）。治疗6个月后，两组患者的MDA、LHP水平均显著降低，GSH-Px水平均显著增高；观察组患者的MDA、LHP水平显著低于对照组，GSH-Px水平显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的白细胞介素-1（IL-1）、白细胞介素-6（IL-6）及超敏C反应蛋白（hs-CRP）水平比较差异无统计学意义（P＞0.05）；治疗6个月后，两组患者的IL-1、IL-6、hs-CRP水平均降低，观察组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）。结论二甲双胍联合DPP-4抑制剂治疗，可显著降低2型糖尿病患者的血糖水平，明显改善患者氧化应激状况，降低患者的炎症反应水平。

ObjectiveTo explore the effects of metformin combined with dipeptidyl peptidase-4 (DPP-4) inhibitor for treatment on blood glucose level, oxidative stress and inflammatory response in patients with type 2 diabetes. MethodA total of 120 patients with type 2 diabetes who were admitted to our hospital from July 2018 to July 2020 were selected as the research objects, and they were divided into observation group and control group by the random number method, with 60 cases in each group. The control group was treated with metformin hydrochloride, based on which the observation group was treated with saxagliptin, for a 6-month continuous treatment course. The blood glucose, oxidative stress indexes and inflammatory factors levels before and after treatment were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in fasting blood glucose (FPG) and 2h postprandial blood glucose (2hPG) levels between the two groups (P＞0.05). After 6 months of treatment, the FPG and 2hPG levels significantly decreased in both groups, and the observation group yielded lower levels as compared with the control group, with statistically significant differences (P＜0.05). There were no statistically significant differences in the levels of malondialdehyde (MDA), lipid hydrogen peroxide (LHP) and glutathione peroxidase (GSH-Px) between the two groups before treatment (P＞0.05). After 6 months of treatment, the MDA and LHP levels significantly decreased, whereas the GSH-Px level significantly increased in both groups, and the patients in the observation group obtained lower levels of MDA and LHP, whereas a higher level of GSH-Px as compared with the control group, with statistically significant differences (P＜0.05). There were no statistically significant differences in the levels of interleukin-1 (IL-1), interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) between the two groups before treatment (P＞0.05). After 6 months of treatment, the levels mentioned above decreased in both groups, and the levels of the observation group were significantly lower than those of the control group, and the differences were statistically significant (P＜0.05). ConclusionMetformin combined with DPP-4 inhibitor for treatment can significantly decrease blood glucose level in patients with type 2 diabetes, significantly improve the oxidative stress status of patients, and reduce the levels of inflammatory response in patients.